Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
CONCLUSION: At the current price, MIRV for PROC with high-FRα expression is not the cost-effective strategy in the US. However, its treatment has higher health benefits in bevacizumab-naïve patients, which is likely to be an alternative.PMID:38576343 | DOI:10.3802/jgo.2024.35.e71 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Youwen Zhu Yinxin Lin Kun Liu Hong Zhu Source Type: research
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer
CONCLUSION: This study could not demonstrate that adding Bev to ddTC improves prognosis. Further studies with more cases are warranted.PMID:38576344 | DOI:10.3802/jgo.2024.35.e76 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Hiromi Komazaki Kazuaki Takahashi Hiroshi Tanabe Yuichi Shoburu Misato Kamii Akina Tsuda Motoaki Saito Kyosuke Yamada Hirokuni Takano Hirofumi Michimae Aikou Okamoto Source Type: research
Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study
CONCLUSION: For patients with stage I, low-grade EEC, abnormal p53 expression may be used as an indicator of poor prognosis. Therefore, we suggest considering aggressive adjuvant therapies for these patients.PMID:38576345 | DOI:10.3802/jgo.2024.35.e78 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Yu-Wei Chang Hsiao-Li Kuo Tzu-Chien Chen Jessica Chen Ling Lim Kung-Liahng Wang Jen-Ruei Chen Source Type: research
Patient and clinician priorities for information on treatment outcomes for advanced ovarian cancer: a Delphi exercise
CONCLUSION: Information needs for treatment decision-making in ovarian cancer differ between and within patient and clinician groups. Whilst overall survival and progression free survival are universally accepted as important data items, decision support tools will need to be nuanced to allow presentation of a range of outcomes and associated probabilities, and in a range of formats, that can be tailored to the preferences of clinician and patients.PMID:38576342 | DOI:10.3802/jgo.2024.35.e63 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Kathryn Baxter Heather Agnew Jennie Morgan Cathrine Holland Darren Flynn Richard Edmondson Source Type: research
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
CONCLUSION: At the current price, MIRV for PROC with high-FRα expression is not the cost-effective strategy in the US. However, its treatment has higher health benefits in bevacizumab-naïve patients, which is likely to be an alternative.PMID:38576343 | DOI:10.3802/jgo.2024.35.e71 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Youwen Zhu Yinxin Lin Kun Liu Hong Zhu Source Type: research
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer
CONCLUSION: This study could not demonstrate that adding Bev to ddTC improves prognosis. Further studies with more cases are warranted.PMID:38576344 | DOI:10.3802/jgo.2024.35.e76 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Hiromi Komazaki Kazuaki Takahashi Hiroshi Tanabe Yuichi Shoburu Misato Kamii Akina Tsuda Motoaki Saito Kyosuke Yamada Hirokuni Takano Hirofumi Michimae Aikou Okamoto Source Type: research
Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study
CONCLUSION: For patients with stage I, low-grade EEC, abnormal p53 expression may be used as an indicator of poor prognosis. Therefore, we suggest considering aggressive adjuvant therapies for these patients.PMID:38576345 | DOI:10.3802/jgo.2024.35.e78 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Yu-Wei Chang Hsiao-Li Kuo Tzu-Chien Chen Jessica Chen Ling Lim Kung-Liahng Wang Jen-Ruei Chen Source Type: research
Patient and clinician priorities for information on treatment outcomes for advanced ovarian cancer: a Delphi exercise
CONCLUSION: Information needs for treatment decision-making in ovarian cancer differ between and within patient and clinician groups. Whilst overall survival and progression free survival are universally accepted as important data items, decision support tools will need to be nuanced to allow presentation of a range of outcomes and associated probabilities, and in a range of formats, that can be tailored to the preferences of clinician and patients.PMID:38576342 | DOI:10.3802/jgo.2024.35.e63 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Kathryn Baxter Heather Agnew Jennie Morgan Cathrine Holland Darren Flynn Richard Edmondson Source Type: research
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
CONCLUSION: At the current price, MIRV for PROC with high-FRα expression is not the cost-effective strategy in the US. However, its treatment has higher health benefits in bevacizumab-naïve patients, which is likely to be an alternative.PMID:38576343 | DOI:10.3802/jgo.2024.35.e71 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Youwen Zhu Yinxin Lin Kun Liu Hong Zhu Source Type: research
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer
CONCLUSION: This study could not demonstrate that adding Bev to ddTC improves prognosis. Further studies with more cases are warranted.PMID:38576344 | DOI:10.3802/jgo.2024.35.e76 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Hiromi Komazaki Kazuaki Takahashi Hiroshi Tanabe Yuichi Shoburu Misato Kamii Akina Tsuda Motoaki Saito Kyosuke Yamada Hirokuni Takano Hirofumi Michimae Aikou Okamoto Source Type: research
Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study
CONCLUSION: For patients with stage I, low-grade EEC, abnormal p53 expression may be used as an indicator of poor prognosis. Therefore, we suggest considering aggressive adjuvant therapies for these patients.PMID:38576345 | DOI:10.3802/jgo.2024.35.e78 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Yu-Wei Chang Hsiao-Li Kuo Tzu-Chien Chen Jessica Chen Ling Lim Kung-Liahng Wang Jen-Ruei Chen Source Type: research
Patient and clinician priorities for information on treatment outcomes for advanced ovarian cancer: a Delphi exercise
CONCLUSION: Information needs for treatment decision-making in ovarian cancer differ between and within patient and clinician groups. Whilst overall survival and progression free survival are universally accepted as important data items, decision support tools will need to be nuanced to allow presentation of a range of outcomes and associated probabilities, and in a range of formats, that can be tailored to the preferences of clinician and patients.PMID:38576342 | DOI:10.3802/jgo.2024.35.e63 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Kathryn Baxter Heather Agnew Jennie Morgan Cathrine Holland Darren Flynn Richard Edmondson Source Type: research
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
CONCLUSION: At the current price, MIRV for PROC with high-FRα expression is not the cost-effective strategy in the US. However, its treatment has higher health benefits in bevacizumab-naïve patients, which is likely to be an alternative.PMID:38576343 | DOI:10.3802/jgo.2024.35.e71 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Youwen Zhu Yinxin Lin Kun Liu Hong Zhu Source Type: research
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer
CONCLUSION: This study could not demonstrate that adding Bev to ddTC improves prognosis. Further studies with more cases are warranted.PMID:38576344 | DOI:10.3802/jgo.2024.35.e76 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Hiromi Komazaki Kazuaki Takahashi Hiroshi Tanabe Yuichi Shoburu Misato Kamii Akina Tsuda Motoaki Saito Kyosuke Yamada Hirokuni Takano Hirofumi Michimae Aikou Okamoto Source Type: research
Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study
CONCLUSION: For patients with stage I, low-grade EEC, abnormal p53 expression may be used as an indicator of poor prognosis. Therefore, we suggest considering aggressive adjuvant therapies for these patients.PMID:38576345 | DOI:10.3802/jgo.2024.35.e78 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Yu-Wei Chang Hsiao-Li Kuo Tzu-Chien Chen Jessica Chen Ling Lim Kung-Liahng Wang Jen-Ruei Chen Source Type: research
